Implementing Minor Changes is Hard to Do Under Variations Regulation
This article was originally published in The Gold Sheet
European generic drug makers say that it is difficult to implement Type IA changes under the variations regulation because of all the paperwork involved in submitting these changes to competent authorities. A 26 percent fee hike in filing variations is also making it more costly and difficult for manufacturers to justify making changes.
You may also be interested in...
Minor Changes Still Burdensome to Report Under Revised Variations Regulation, European Industry and Competent Authorities Complain
Proposal could yield a bounty of new options for innovative drug delivery systems.
Data integrity issues were raised in many warning letters to active pharmaceutical ingredient manufacturers over the past four years.